The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

Other (Specify)

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001261249 Levotech, Inc. X Corporation

Name of Issuer Limited Partnership

AGILE THERAPEUTICS INC

Limited Liability Company

Jurisdiction of General Partnership
Incorporation/Organization

DELAWARE

General Partnership
Business Trust
Other (Specific)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

AGILE THERAPEUTICS INC

Street Address 1 Street Address 2

101 POOR FARM ROAD

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

PRINCETON NEW JERSEY 08540-1715 609-683-1880

3. Related Persons

Last Name First Name Middle Name

Altomari Al

Street Address 1 Street Address 2

101 Poor Farm Road

City State/Province/Country ZIP/PostalCode

Princeton NEW JERSEY 08540-1715

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Coiante Scott

Street Address 1 Street Address 2

101 Poor Farm Road

City State/Province/Country ZIP/PostalCode

Princeton NEW JERSEY 08540-1715

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Hong Karen

Street Address 1 Street Address 2

c/o ProQuest Investments 90 Nassau Street, 5th Floor
City State/Province/Country ZIP/PostalCode

Princeton NEW JERSEY 08542

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Pellegrini Lorenzo

Street Address 1 Street Address 2
Capital Investments III I P. 47 Hulfish Street Suite 310

c/o Care Capital Investments III LP 47 Hulfish Street, Suite 310

City State/Province/Country ZIP/PostalCode

Princeton NEW JERSEY 08542

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Lele Abhijeet

Street Address 1 Street Address 2

630 Fifth Avenue Suite 1965

City State/Province/Country ZIP/PostalCode

New York NEW YORK 10111

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing

Banking & Financial Services Biotechnology Restaurants
Commercial Banking Health Insurance Technology

Insurance Hospitals & Physicians Computers

Investment Banking X Pharmaceuticals Telecommunications

Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel an investment company under Real Estate

the Investment Company

Act of 10403

Real Estate

Airlines & Airports

Commercial

Lodging & Convent

Act of 1940? Commercial Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

Business Services Residential Other

Energy Other Real Estate

Coal Mining
Electric Utilities

Environmental Services

Energy Conservation

Other Energy

Oil & Gas

Revenue Range	OR	Aggregate Net Asset Value Range				
X No Revenues		No Aggregate Net Asset Value		ue		
\$1 - \$1,000,000		\$1 - \$5,000,000				
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25	,000,000			
\$5,000,001 - \$25,000,000		\$25,000,001 - \$5	0,000,000			
\$25,000,001 - \$100,000,000		\$50,000,001 - \$1	00,000,000			
Over \$100,000,000		Over \$100,000,0				
Decline to Disclose		Decline to Disclo	ose			
Not Applicable		Not Applicable				
6. Federal Exemption(s) and Ex	cclusion(s) Claim	ed (select all that a	apply)			
Rule 504(b)(1) (not (i), (ii) o	r (iii))	Rule 505				
Rule 504 (b)(1)(i)		X Rule 506				
Rule 504 (b)(1)(ii)		Securities Act Section 4(5)				
Rule 504 (b)(1)(iii)		Investment Company Act Section 3(c)				
		Section 3(c)(1)	Section 3(c)(9)		
		Section 3(c)(2)	Section 3(c)(10)		
		Section 3(c)(3)	Section 3(c)(11)		
		Section 3(c)(4)	Section 3(c)(12)		
		Section 3(c)(5)	Section 3(c)(13)		
		Section 3(c)(6)	Section 3(c)(14)		
		Section 3(c)(7	7)			
7. Type of Filing						
New Notice Date of First S X Amendment	ale 2010-05-25	First Sale Yet to	Occur			
8. Duration of Offering						
Does the Issuer intend this offe	ring to last more	than one vear? X	Yes No			
9. Type(s) of Securities Offered	_	-				
	. (00-000 0-0	FF-37				
X Equity			Pooled Investment Fund Interests			
	Debt			Tenant-in-Common Securities		
Option, Warrant or Other Ri	-	•	Mineral F	Property Securities		
Security to be Acquired Upo Other Right to Acquire Secu	tion, Warrant or	on, Warrant or Other (describe)				
10. Business Combination Tran	saction					
Is this offering being made in case a merger, acquisition or exchange.		business combina	tion transac	etion, such as Yes X No		
Clarification of Response (if Ne	ecessary):					
11. Minimum Investment						

Recipient

12. Sales Compensation

Minimum investment accepted from any outside investor \$0 USD

(Associated) Broker or Dealer X None

(Associated) Broker or Dealer CRD Number X None

Street Address 1

Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply) Check "All States" or check individual States

All States Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$45,100,660 USD or Indefinite

Total Amount Sold \$33,060,670 USD

Total Remaining to be Sold \$12,039,990 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

14

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$1.600,000 USD X Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AGILE THERAPEUTICS INC	/s/ Al Altomari	Al Altomari	President and Chief Executive Officer	2011-07-11

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.